The approval of novel orphan drug designations continues to grow, while many existing rare disease therapies are receiving approval for expanded indications.…


In Amgen-Sandoz SCOTUS case, biosim makers lambaste ruling's 6-month exclusivity gift

EMA raises manufacturing questions over Novartis biosimilar production

Novartis building an antibiotics plant in Slovenia

Sandoz head: Enbrel biosimilar Erelzi won't launch before 2018, delayed by legal battle

Patient requests buoy oral meds from Biogen, Novartis in crowded MS market